Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 2/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269858 | 0.83 | KDM4E (0.53) | KDM4EPKML3MBTL1RORB | |
| SCHEMBL25779065 | 0.83 | KDM4E (0.50) | KDM4EPKMDAOTDP1NPC1 | |
| SCHEMBL5011859 | 0.80 | KDM4E (0.47) | KDM4EPKMDAOTDP1NPC1 | |
| SCHEMBL25779061 | 0.80 | CDC7 (0.50) | KDM4EPKML3MBTL1RORB | |
| SCHEMBL24508613 | 0.79 | KDM4E (0.46) | KDM4EPKMDAOTDP1NPC1 | |
| SCHEMBL14711219 | 0.79 | KDM4E (0.46) | KDM4EPKMRORBPTPN1 | |
| SCHEMBL10268828 | 0.79 | KDM4E (0.49) | KDM4EPKMDAONPC1 | |
| SCHEMBL14564467 | 0.79 | KDM4E (0.55) | KDM4EPKMTDP1NPC1RAB9A | |
| SCHEMBL24508647 | 0.79 | KDM4E (0.46) | KDM4EPKMPTPN1 | |
| SCHEMBL3105240 | 0.78 | KDM4E (0.59) | KDM4EPKMDAOTDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | KDM4E 3497/4885PKM 979/4885DAO 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.